Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Tripathy Discusses Bisphosphonate Studies

March 15th 2011

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer.

Dr. Pearlstone on Biomarker Testing in the Community

March 14th 2011

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting

Crisis Averted? Manufacturers Scurry to Meet Demand for Drugs

March 12th 2011

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

The Emperor of All Maladies: Documenting Cancer's Long Reign

March 12th 2011

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

Brufsky Urges Caution in Translating Assays

March 10th 2011

Amid advances in gene-based cancer diagnostics, questions about the best use of molecular and cellular assays in practice are growing along with the new options for clinicians.

Net Guides: Ovarian Cancer

March 10th 2011

Useful Online Resources and Clinical Trials for Ovarian Cancer

FDA Requests Label Change for Generic Docetaxel

March 9th 2011

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

From the Editor: Internet Analysis Raises Questions in Rare Cancer Care

March 6th 2011

The Internet has been employed in a variety of interesting ways to foster clinical or research agendas.

Moving Beyond Standard of Care: Novel Treatments in Gynecologic Cancer

March 4th 2011

In the United States, gynecologic cancers affect nearly 80,000 women annually and are the cause of death in more than 25,000 women.

Ovarian Cancer Screening Not Very Effective

March 4th 2011

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the Literature

March 3rd 2011

In May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.

False-Positive Mammograms Lead to Anxiety and Quality-of-Life Issues

March 2nd 2011

A false-positive result on a mammogram may trigger anxiety and decrease quality of life, and the effects may remain apparent a year later, new data suggest.

Breastfeeding May Benefit Childhood Cancer Survivors

March 2nd 2011

For women who have survived childhood cancer, breastfeeding may help counter some of the long-term complications that occur as a result of their prior cancer treatments, researchers say.

SABCS Coverage: Adding Everolimus to Tamoxifen Improves Outcomes in Metastatic Breast Cancer

March 2nd 2011

Everolimus (Afinitor) added to tamoxifen delayed tumor progression in patients with hormone receptor (HR)-positive, HER2-negative, advanced metastatic breast cancer

SABCS Coverage: Trastuzumab Superior to Lapatinib in HER2-Positive Breast Cancer, But Combination Is Best

March 2nd 2011

Two trials explored the role of lapatinib (Tykerb) as neoadjuvant therapy in early-stage HER2-positive breast cancer and concluded that its effectiveness is statistically no better than standard trastuzumab (Herceptin) therapy

SABCS Coverage: Denosumab Bests Zoledronic Acid at Preventing Bone Complications in Patients With Breast Cancer

March 2nd 2011

Investigators for Study 136 say that an additional 4 months of follow-up data have confirmed earlier findings that denosumab (Xgeva) is superior to zoledronic acid (Zometa) at preventing skeletal-related events

SABCS Coverage: Zoledronic Acid Improves Disease-Free Survival in Postmenopausal or Older Women Only

March 2nd 2011

Adjuvant treatment of stage II and III breast cancer with zoledronic acid (Zometa) failed to improve disease-free survival (DFS) in the large

SABCS Coverage: Fulvestrant Prolongs Time to Progression in Breast Cancer

March 2nd 2011

Women with untreated advanced breast cancer had a trend toward greater clinical benefit with fulvestrant (Faslodex) versus anastrozole (Arimidex) as first-line hormonal therapy

SABCS Coverage: Aromatase Inhibitors Increase Cardiotoxicity Risk in Women With Pre-existing Heart Disease

March 2nd 2011

Aromatase inhibitor use appears to increase the risk of cardiotoxicity in women with early-stage breast cancer, albeit slightly.

SABCS Coverage: MA.27 Study Finds Exemestane and Anastrozole Comparable

March 2nd 2011

Exemestane (Aromasin) was no better than anastrozole (Arimidex) at reducing cancer recurrence in postmenopausal women with hormone receptor-positive primary breast cancer